Original language | English (US) |
---|---|
Pages (from-to) | 1807-1816 |
Number of pages | 10 |
Journal | Journal of Vascular and Interventional Radiology |
Volume | 21 |
Issue number | 12 |
DOIs |
|
State | Published - Dec 2010 |
Keywords
- Abbreviations
- H-E
- Hematoxylin and eosin
- NADH
- Nicotinamide adenine dinucleotide
- RCC
- RCP
- RF
- Radiofrequency
- Renal cell carcinoma
- Research consensus panel
- SIR
- Society of Interventional Radiology
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Development of a research agenda for percutaneous renal tumor ablation : Proceedings from a multidisciplinary research consensus panel. / Georgiades, Christos S.; Rodriguez, Ronald; Littrup, Peter J. et al.
In: Journal of Vascular and Interventional Radiology, Vol. 21, No. 12, 12.2010, p. 1807-1816.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Development of a research agenda for percutaneous renal tumor ablation
T2 - Proceedings from a multidisciplinary research consensus panel
AU - Georgiades, Christos S.
AU - Rodriguez, Ronald
AU - Littrup, Peter J.
AU - Frangakis, Constantine E.
AU - Leveille, Raymond
AU - Ahrar, Kamran
AU - Atwell, Thomas D.
AU - Cadeddu, Jeffrey A
AU - Trimmer, Clayton K
AU - Durack, Jeremy C.
AU - Hammers, Hans
AU - Meng, Maxwell V.
AU - Raman, Steven
AU - Solomon, Stephen B.
AU - Zagoria, Ronald J.
AU - McLennan, Gordon
AU - Laberge, Jeanne M.
AU - Gervais, Debra A.
AU - Kee, Stephen T.
N1 - Funding Information: The RCP Meeting was sponsored by the SIR foundation . Funding Information: R.R. has received research support from Endocare (Irvine, California); J.C. is a consultant for and has sponsored research from Ethicon (Somerville, New Jersey); C.T. is a paid consultant for Cook (Bloomington, Indiana) and Angiotech (Vancouver, BC, Canada); H.J.H. has received research funding from Novartis (Basel, Switzerland), Pfizer (New York, New York), and GlaxoSmithKline (Research Triangle Park, North Carolina); S.R. has received sponsorship of research from Covidien (Mansfield, Massachusetts) and Endocare and is a paid consultant for Covidien, Endocare, Bayer (Shawnee Mission, Kansas), and Novartis; S.B.S. is a paid consultant for General Electric (Milwaukee, Wisconsin) and Johnson & Johnson (Warren, New Jersey) and received research support from Angiodynamics (Queensbury, New York) and General Electric ; R.J.Z. has received sponsorship of research from Covidien ; G.M. is a paid consultant for Bard (Tempe, Arizona), Cook, Medtronic (Minneapolis, Minnesota), and Siemens Medical Systems (Iselin, New Jersey) and has received research support from Bard ; and D.A.G. has received sponsorship of research from Covidien . None of the other authors have identified a conflict of interest.
PY - 2010/12
Y1 - 2010/12
KW - Abbreviations
KW - H-E
KW - Hematoxylin and eosin
KW - NADH
KW - Nicotinamide adenine dinucleotide
KW - RCC
KW - RCP
KW - RF
KW - Radiofrequency
KW - Renal cell carcinoma
KW - Research consensus panel
KW - SIR
KW - Society of Interventional Radiology
UR - http://www.scopus.com/inward/record.url?scp=78649511987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649511987&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2010.10.002
DO - 10.1016/j.jvir.2010.10.002
M3 - Comment/debate
C2 - 21111363
AN - SCOPUS:78649511987
SN - 1051-0443
VL - 21
SP - 1807
EP - 1816
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 12
ER -